This document discusses the one compartment model for intravenous infusion. It explains that IV infusion maintains a stable drug concentration over a long period by administering the drug at a constant zero-order rate. The key aspects covered include:
- Reaching a steady state concentration where the infusion rate equals the elimination rate.
- Calculating the steady state concentration, elimination rate constant, and other pharmacokinetic parameters.
- The time required to reach steady state being dependent on the drug's half-life, not the infusion rate.
- Using a loading dose for drugs with long half-lives to quickly reach the steady state concentration upon starting infusion.
KINETICS OF MULTIPLE DOSING under the Unit Multicompartment Models According to New PCI syllabus 2017 by Ms. Preeti Patil-Vibhute, Assistant Professor, Sarojini College of Pharmacy, Kolhapur.
The presentation concisely describes the different pharmacokinetic parameters and basics of compartment modelling. It will help undergraduate students to understand the basic concepts of Biopharmaceutics.
PHARMACOKINETIC MODELS
Drug movement within the body is a complex process. The major objective is therefore to develop a generalized and simple approach to describe, analyse and interpret the data obtained during in vivo drug disposition studies.
The two major approaches in the quantitative study of various kinetic processes of drug disposition in the body are
Model approach, and
Model-independent approach (also called as non-compartmental analysis).
DISSOLUTION
Dissolution is defined as a process in which a solid substance solubilises in a given solvent.
(i.e. mass transfer from the solid surface to the liquid phase.)
Three Theories:
Diffusion layer model / Film theory
Danckwert’s model / Penetration or Surface renewal theory
Interfacial barrier model / Double barrier or Limited solvation theory
KINETICS OF MULTIPLE DOSING under the Unit Multicompartment Models According to New PCI syllabus 2017 by Ms. Preeti Patil-Vibhute, Assistant Professor, Sarojini College of Pharmacy, Kolhapur.
The presentation concisely describes the different pharmacokinetic parameters and basics of compartment modelling. It will help undergraduate students to understand the basic concepts of Biopharmaceutics.
PHARMACOKINETIC MODELS
Drug movement within the body is a complex process. The major objective is therefore to develop a generalized and simple approach to describe, analyse and interpret the data obtained during in vivo drug disposition studies.
The two major approaches in the quantitative study of various kinetic processes of drug disposition in the body are
Model approach, and
Model-independent approach (also called as non-compartmental analysis).
DISSOLUTION
Dissolution is defined as a process in which a solid substance solubilises in a given solvent.
(i.e. mass transfer from the solid surface to the liquid phase.)
Three Theories:
Diffusion layer model / Film theory
Danckwert’s model / Penetration or Surface renewal theory
Interfacial barrier model / Double barrier or Limited solvation theory
Pharmacokinetics of IV infusion, one-compartment open modelAsuprita Patel
OCOM is the simplest model that represents the body as a single homogeneous system. Rapid i.v. injection is unsuitable when the drug has potential to precipitate toxicity or when maintenance of a stable concentration or amount of drug in the body is desired.
In such situation, the drug is administered at a constant rate by i.v. infusion.
This presentation is about the process by which prolonged therapeutic activity of drug is achieved and it's importance. By this presentation you will learn about dosage regimen, steady state concentration, principle of superposition, drug accumulation, repetitive intravenous injections etc. By this you will also learn how to adjust the dose to the patient.
Biopharmaceutics & Pharmacokinetics (Ultimate final note)MdNazmulIslamTanmoy
Intravenous Infusion (IV): Define intravenous infusion. Write down advantages and disadvantages of intravenous infusion,
Write down the pharmacokinetics of IV infusion, Calculate the plasma drug concentration at steady-state after IV infusion, Determine the half life (t1/2) by IV infusion method, Show that in case of IV infusion the time to reach 99% steady-state is 6.65 t1/2.
Multiple-Dosage Regimens: Write a short note on Multiple-Dosage Regimens. What are the basic considerations for multiple dosage regimen?, What are the purposes of multiple-dosage regimens (MDR)? Write down the importance of MDR, Write short note on repetitive intravenous injections, Prove that C∞av is not arithmetic average of C∞max and C∞min, Give brief description on superposition principle and Plateau principle?.
Individualization: Write down about individualization of drug dosing regimen? What are the advantages of individualization? How will you optimizing dosage regimen?, What are the sources of variability in drug response? What are the causes of Inter subject Pharmacokinetics Variability? Write down the steps involved in individualization of dosage regimen?, Write short note on – dosing of drug in obese patient and also discuss about dosing of drug in neonates, infants and children?, Write down about dosing of drug in elderly and hepatic disease? Give some examples of drugs who's conc. Changes due to hepatic impairment?, Explain some clinical experience with individualization and optimization based on plasma drug levels?
NON-linear pharmacokinetics: Derive the Michaelis-Menten Equation or Non-Liner pharmacokinetic and Linear pharmacokinetic model, Define non-linear pharmacokinetics. Why it is called dose dependent pharmacokinetics?, Why Michaelis-Menten equation is termed as mixed order kinetics?, A given drug is metabolized by capacity-limited pharmacokinetics. Assume KM is 50훍g/mL, Vmax is 20훍g/mL per hour and apparent VD is 20 L/kg, Differentiate between linear & non-linear Pharmacokinetics.
Non-compartment model: Briefly describe compartment model?, Briefly describe non-compartment model?, What is MRT? Write down the importance of MRT?, What is MAT? Write down the importance of MAT?, Compare between compartment model and non-compartment models.
Calculation of the plasma drug levels after a single dose IVinfusion..pptxSARADPAWAR1
Drugs administered by IV route may either be given at once (as a bolus dose) or by slower IV infusion over a definite time such as Phenytoin which must be given slowly, no greater than 50 mg/min (and preferably 25 mg/min or less) in adults. Such drugs are infused slowly through a vein into the blood at a constant rate (zero order input) which allows precise control of plasma drug concentrations.
Pharmacokinetics (PK) is the study of how the body interacts with administered substances for the entire duration of exposure (medications for the sake of this article). This is closely related to but distinctly different from pharmacodynamics, which examines the drug's effect on the body more closely.
clinical pharmacokinetics half-life first-order elimination zero order elimination steady-state conc applied aspect of steady-state applied aspect of half-life advantage and disadvantage
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
2. Intravenous infusion
When a drug is administered intravenously at a constant rate (zero order) over a long period of time ,
it is known as IV infusion. The duration of the constant rate infusion is much longer than the half life of
the drug. E.g. antibiotics, theophylline, procainamide etc.
Why IV infusion?
•When the drug has potential to precipitate toxicity
•When a stable concentration of the drug is to be maintained for the therapeutic effect.
Advantages
•Ease of control of rate of infusion to fit individual patient needs.
•Prevents fluctuating maxima and minima (peak and valley) plasma level, desired especially when the
drug has a narrow therapeutic index.
•Other drugs, electrolytes and nutrients can be conveniently administered simultaneously by the same
infusion line in critically ill patients.
3. Zero - Order
Kinetics
The rate of change in concentration is expressed as :
𝒅𝑪
𝒅𝒕
= - K . Cn where n is the order of the reaction
for zero order kinetics n=0
𝒅𝑪
𝒅𝒕
= - K0 C0 = - K0 ( zero order rate constant in mg/min)
Rearranging the equation we get:
dC= - K0 t
Integrating both sides
C-C0= - K0 t
C= C0 - K0 t
C0 is conc of drug at t=0
C is conc of drug yet to
Undergo reaction at time t
Zero order processes can be defined
as the one whose rate is independent
of the concentration of drug
undergoing reaction i.e. the rate
cannot be increased further by
increasing the concentration of
reactants.
4. IV Infusion Model
DRUG
BLOOD AND OTHER
BODY TISSUES
ELIMINATION
R0 KE
Zero-order
Infusion rate
R0- Zero order infusion rate
KE- Elimination rate constant
5. At any time during infusion , the rate of change in the amount of drug in the body, dX/dt is the difference between
the zero order rate of drug infusion R0 and first order rate of elimination, -KEX
𝑑𝑋
𝑑𝑡
= R0 – KEX - (1)
Integrating eq.(1) yields
X =
𝑅0
𝐾 𝐸
(1- 𝑒−𝐾𝐸𝑡) - (2)
Since X= Vd.C where Vd is the volume of distribution and C is the Conc. of drug, eq. (2) can be transformed as:
C =
𝑅0
𝐾 𝐸
𝑉 𝑑
(1- 𝑒−𝐾𝐸𝑡 ) =
𝑅0
𝐶𝑙 𝑇
(1- 𝑒−𝐾𝐸𝑡 ) - (3)
6. Plasma concentration – Time profile
1. Initially the drug enters the body at
constant rate
2. The infusion rate R0 > KEX (elimination
rate).
3. As infusion time progresses the rate of
infusion equalizes with the elimination rate
of the drug
4. This stage is called the steady state
concentration /plateau/ infusion
equilibrium. (CSS )
5. At this stage concentration of drug in
plasma approaches a constant value.
7. At steady state , the rate of change of amount of drug in the body is zero, hence the eq. (1) becomes:
𝑑𝑋
𝑑𝑡
= R0 – KEX -(1)
0= R0 – KEXSS
R0 = KEXSS - (4)
Transforming to concentration terms and rearranging the equation:
CSS =
𝑅0
𝐾 𝐸
𝑉 𝑑
=
𝑅0
𝐶𝑙 𝑇
𝑖𝑛𝑓𝑢𝑠𝑖𝑜𝑛 𝑟𝑎𝑡𝑒
𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒
- (5)
KE- Elimination rate constant
CSS- Concentration of the drug at steady state
XSS- Amount of the drug in the body at steady state
8. Calculating KE by using semi logarithmic
plot
Alternative method : During infusion the KE
can be calculated:
𝑅0
𝐶𝑙 𝑇
= CSS -(5)
C= CSS (1-𝑒−𝐾𝐸𝑡) - (6)
[𝐶 𝑆𝑆
−𝐶
𝐶 𝑆𝑆
] = 𝑒−𝐾𝐸𝑡 - (7)
log [𝐶 𝑆𝑆
−𝐶
𝐶 𝑆𝑆
] = −𝐾𝐸𝑡
2.303
- (8)
9. Half life of drug in IV infusion
•The time to reach steady state concentration is
dependent upon the elimination half life and
not on the infusion rate.
•If n is the number of half lives passed since the
start of infusion, the eq. (6) can be written as:
C= CSS {1- ( 𝟏
𝟐) n }
Where C is the concentration of the drug after
nth half life
•The percent of CSS achieved at the end of each
half life is the sum of CSS at previous half life
and the concentration of drug remaining after
a given half life
Half life % remaining % CSS achieved
1 50 50
2 25 50+25=75
3 12.5 75+ 12.5= 87.5
4 6.25 87.5+ 6.25= 93.75
5 3.125 93.75+ 3.125= 96.875
6 1.562 96.875+ 1.562= 98.437
7 0.781 98.437+ 0.781= 99.218
For therapeutic purpose, more than 90% of CSS is desired
which is reached in 3.3 half lives. It takes 6.6 half lives to
reach 99% of CSS. Shorter the half life, sooner the CSS
reached. E.g. Penicillin G with half life of 30 mins.
10. Infusion plus Loading Dose
What is loading dose?
•For drugs having longer half lives, like phenobarbital (5 days), it takes longer time to achieve the
steady state concentration. To overcome the sub therapeutic concentration of these drugs, an IV
loading dose large enough is administered to reach the steady state immediately
•After the loading dose is administered, the IV infusion is given immediately at a rate enough to
maintain this concentration.
Some important drugs that require loading dose:
• Amiodarone- Loading dose of 150 mg IV in 10 minutes slowly, followed by IV infusion of 540 mg over
18 hours.
•Streptokinase- Loading dose of 250,000 IU, followed by IV infusion of 100,000 IU/hr for 72 hours for
recurring pulmonary emboli and DVT.
•Succinylcholine- Loading dose of 0.3-1.1 mg/kg over 30 sec for surgical procedures and a continuous
IV infusion of 0.5-1.0 mg/min for prolonged muscle relaxation.
11. Calculating the loading dose
X= Vd.C
Taking X0,L as the loading dose,
X0,L= CSS. Vd - (9)
Substituting CSS= R0/ KEVd in eq. (9)
X0,L=
𝑹 𝟎
𝑲 𝑬
- (10)
Hence the eq. describing the plasma conc.
Following the IV loading dose and IV infusion
is:
C=
X0,L
Vd
𝒆−𝑲𝑬𝒕 +
𝑹 𝟎
𝑲 𝑬
𝑽 𝒅
(1-𝒆−𝑲𝑬𝒕) - (11)
12. Assessment of Pharmacokinetic
Parameters
•Apparent volume of distribution
Vd =
𝑹 𝟎
𝑲 𝑬
.𝑪𝑺𝑺
•Total systemic clearance
ClT =
𝑹 𝟎
𝑪 𝑺𝑺
•These two parameters can also be calculated from the total area under the curve (AUC) till the
end of infusion:
AUC =
𝑹 𝟎
𝑻
𝑲 𝑬
𝑽 𝒅
=
𝑹 𝟎
𝑻
ClT
= CSS. T
Where T is the infusion time.
13. References:
•Biopharmaceutics and Pharmacokinetics by D. M. Brahmankar and Sunil B. Jaiswal
•Guidance on Drug Doses Loading Doses for Primary Care Health Care Professionals by NHS
http://www.southernhealth.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=30182